Network Meta-analysis of Chinese patent medicines in treatment of idiopathic membranous nephropathy.
10.19540/j.cnki.cjcmm.20230418.501
- Author:
Jia MA
1
;
Yan-Jie HOU
2
;
Yi-Ou ZHANG
2
;
Guang-Zhen LIU
2
Author Information
1. Shanxi University of Chinese Medicine Taiyuan 030024, China.
2. Shanxi Institute of Traditional Chinese Medicine Taiyuan 030012, China.
- Publication Type:Journal Article
- Keywords:
Chinese patent medicine;
idiopathic membranous nephropathy;
network Meta-analysis
- MeSH:
Humans;
Nonprescription Drugs/therapeutic use*;
Network Meta-Analysis;
Glomerulonephritis, Membranous/drug therapy*;
Bayes Theorem;
Capsules;
Delayed-Action Preparations;
Drugs, Chinese Herbal/adverse effects*;
Tablets
- From:
China Journal of Chinese Materia Medica
2023;48(13):3650-3663
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to systematically evaluate the efficacy and safety of different Chinese patent medicines in the treatment of idiopathic membranous nephropathy. The relevant randomized controlled trial(RCT) was retrieved from PubMed, EMbase, Cochrane Library, CNKI, SinoMed, Wanfang, and VIP with the time interval from database inception to December 2022. The Cochrane risk of bias assessment tool was employed to evaluate the quality of the included RCT, and Stata 15.0 and GEMTC to perform the Bayesian network Meta-analysis. Finally, 51 RCTs were included, involving 9 Chinese patent medicines and 3 591 patients. The results of network Meta-analysis showed that in terms of the total effective rate and the increase in plasma albumin, the top three interventions were Zhengqing Fengtongning Sustained Release Tablets + conventional western medicine, Bailing Capsules + conventional western medicine, and Tripterygium Glycosides Tablets + conventional western medicine. In terms of reducing 24-hour urine total protein, the top three interventions were Zhengqing Fengtongning Sustained Release Tablets + conventional western medicine, Shenfukang Capsules +conventional western medicine, and Huangkui Capsules + conventional western medicine. In terms of reducing serum creatinine, the top three interventions were Shenfukang Capsules + conventional western medicine, Bailing Capsules + conventional western medicine, and Zhengqing Fengtongning Sustained Release Tablets + conventional western medicine. In terms of safety, Chinese patent medicines combined with conventional western medicine had fewer adverse reactions than the control group. The results suggest that Chinese patent medicines combined with conventional western medicine can improve the therapeutic effect on idiopathic membranous nephropathy, and differentiated medications can be adopted according to the specific symptoms of patients in clinical treatment. Further validation needs to be carried out in the future with multi-center, large-sample, and high-quality RCT.
